PARP inhibitors in melanoma treatment: potential, challenges, and future directions by Angela Anaeme, Karen Moussa, Abdallah N. Mansour, George Nassief, George Ansstas

Get full text

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors by Douglas E Feltner, Adil Daud, Brent A Hanks, Shailender Bhatia, Michael K Wong, Sunandana Chandra, Trisha M Wise-Draper, Philip A Friedlander, Melissa A Burgess, Glenn J Hanna, C Lance Cowey, George Ansstas, Ciara M Kelly, Mohammed M Milhem, Cesar A Perez, Ryan M Weight, Alice S Bexon, Douglas E Laux, Theresa M Medina, Steven J O’Day, Timothy S Kristedja, Weston L Daniel, Scott Mix, Laurel Sindelar, Martin F Bexon, Robert E Michel

Get full text